Agios Pharmaceuticals (AGIO) Other Accumulated Expenses (2012 - 2017)

Agios Pharmaceuticals has reported Other Accumulated Expenses for 6 years, with the latest figure at $1.3 million in Q1 2017.

• For the quarter ending Q1 2017, Other Accumulated Expenses rose 386.84% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2017 stood at $1.3 million (up 386.84% YoY), and the FY2016 full-year result was $168000.0, down 87.21% from the prior year.
• Other Accumulated Expenses for Q1 2017 stood at $1.3 million, up from $168000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $1.3 million in Q4 2015, with the low at $6000.0 in Q4 2014.
• Historically, Other Accumulated Expenses has averaged $489375.0 across 5 years, with a median of $385500.0 in 2013.
• Annual changes were most pronounced in 2014 — Other Accumulated Expenses plunged 95.71% — and 2015, when it surged 21800.0%.
• Agios Pharmaceuticals' Other Accumulated Expenses stood at $140000.0 in 2013, then sank by 95.71% to $6000.0 in 2014, then surged by 21800.0% to $1.3 million in 2015, then tumbled by 87.21% to $168000.0 in 2016, then jumped by 670.83% to $1.3 million in 2017.
• The last three Other Accumulated Expenses figures came in at $1.3 million (Q1 2017), $168000.0 (Q4 2016), and $538000.0 (Q3 2016), per Business Quant data.